强直性脊柱炎患者血清MMP-3和IL-15水平的表达及临床意义

目的:研究强直性脊柱炎(AS)患者血清基质金属蛋白酶-3(MMP-3)和白细胞介素-15(IL-15)水平的表达及临床意义。方法:选取从2015年1月至2016年9月在我院就诊的AS患者50例。根据Bath强直性脊柱炎疾病活动性指数(BASDAI)将患者分为A组(指数≥6)28例,B组(指数6)22例。此外,按照Bath强直性脊柱炎功能指数(BASFI)将患者分为Ⅰ组(指数≥6)29例,Ⅱ组(指数6)21例。另取同期健康体检者30例记为对照组。分别对比A、B组以及Ⅰ、Ⅱ组与对照组的血清MMP-3和IL-15水平,并作相关性分析。结果:A组MMP-3、IL-15水平均显著高于B组及对照组,而B组又显著高于对照组,差异均有统计学意义(均P0.05)。Ⅰ组MMP-3、IL-15水平均显著高于Ⅱ组与对照组,而Ⅱ组又显著高于对照组,差异均有统计学意义(均P0.05)。经相关性分析可得,AS患者BASDAI、BASFI与MMP-3、IL-15均呈显著正相关(P0.05)。结论:血清MMP-3和IL-15在AS患者中高表达,且在疾病的发生发展中具有重要作用,可作为临床判断AS患者病情严重程度的血清学指标。     

强直性脊柱炎生物治疗的现状及新进展

强直性脊柱炎是一种以脊柱病变为主的慢性痫,累及骶髂关节,引起脊柱强直和纤维化,造成不同程度的眼、肺、肌肉、骨骼病变,属自身免疫性疾病。强直性脊柱炎的致病机制仍未完全明了,但在治疗方面,生物治疗策略取得了可喜的新经验,生物药物展现出良好的应用前景。,     

肿瘤坏死因子拮抗剂对强直性脊柱炎患者血清相关细胞因子变化的影响及其机制研究

目的:观察肿瘤坏死因子(TNF)拮抗剂对强直性脊柱炎(AS)患者血清中IL-6、IL-17、IL-21、IL-23、TNF-α、TGF-β1表达的影响,结合临床指标的变化探讨肿瘤坏死因子拮抗剂治疗AS的机制与疗效。方法:治疗组应用益赛普联合西乐葆,益赛普25 mg,皮下注射,连用8周,治疗前后评估晨僵VAS评分、腰背痛VAS评分、Bath强直性脊柱炎功能指数(BASFI)及血沉等指标,记录不良反应。用酶联免疫吸附法检测25例肿瘤坏死因子拮抗剂联合COX-2抑制剂治疗前、治疗第4周和治疗8周后AS患者血清中IL-6、IL-17、IL-21、IL-23、TNF-α、TGF-β1的表达情况,检测对照组(20例单独应用COX-2抑制剂的AS患者)治疗前、治疗后的细胞因子水平。结果:肿瘤坏死因子拮抗剂组患者血清中IL-6、IL-17、IL-23、TNF-α的表达在治疗第4周和治疗8周后较本组治疗前及对照组均有明显下降(P0.05);细胞因子IL-21、TGF-β1的表达水平较本组治疗前及对照组无明显降低(P0.05);对照组患者血清中IL-6、IL-17、IL-21、IL-23、TNF-α、TGF-β1的表达在治疗后较治疗前均无明显下降(P0.05);治疗组应用肿瘤坏死因子拮抗剂后较治疗前晨僵及腰背痛VAS评分、BASFI、血沉均显著改善(P0.05),临床疗效优良率为88.0%,对照组优良率为50.0%,有显著差异(P0.05),且治疗组不良反应轻微。结论:肿瘤坏死因子拮抗剂可能是通过降低AS患者血清中一系列细胞因子的表达水平,改善患者的免疫功能及临床症状,延缓了病程进展。但由于病例较少,肿瘤坏死因子拮抗剂联合COX-2抑制剂治疗AS患者的疗效需要在临床中进一步观察。     

小鼠急性病毒性心肌炎对TNF-α表达的影响

目的:探讨肿瘤坏死因子(TNF-α)在柯萨奇病毒B3(CVB3)感染所致的急性病毒性心肌炎中的表达。方法:用不同剂量CVB3感染小鼠建立病毒性心肌炎感染模型,测定TNF-α含量并观察心肌病变情况。结果:感染后3d开始TNF-α的表达明显升高且高剂量感染组明显高于中、低剂量感染组。结论:在CVB3感染早期TNF-α表达升高且与病毒感染量有关。     

蝮蛇毒介导小鼠急性心肌损伤及心肌组织TNF-α表达的研究

目的探讨蝮蛇毒介导小鼠心肌组织中TNF-α蛋白表达变化与不同蝮蛇毒剂量、中毒时间的关系。方法确定LD50蝮蛇毒注射剂量。将96只小鼠随机分为空白对照组、蛇毒低剂量(0.5mg/kg)组、蛇毒高剂量(1.0mg/kg)组,并按中毒时间设4水平组,即3、6、24、48h组,采集小鼠心肌标本,免疫组化检测心肌组织中TNF-α蛋白的表达情况。结果蛇毒低剂量组及蛇毒高剂量组小鼠心肌TNF-α蛋白表达明显高于空白对照组(均P0.05);而蛇毒高剂量组明显高于低剂量组(P0.05);6h组明显高于3h组(P0.05);24h组高于6h组(P0.05);48h组高于24h组(P0.05)。随着蝮蛇毒剂量的增加、中毒时间的延长,心肌TNF-α蛋白的表达越高。结论蝮蛇毒导致小鼠急性心肌损伤,TNF-α蛋白表达增高,且随着蝮蛇毒剂量的增加、中毒时间的延长,心肌TNF-α蛋白的表达越高,呈一定的时间、剂量效应趋势,提示TNF-α蛋白过度表达可能是蝮蛇毒导致小鼠急性心肌损伤的机制之一。     

局部应用依那西普治疗强直性脊柱炎髋关节受累的临床疗效分析

目的：评价局部应用依那西普治疗强直性脊柱炎髋关节受累的短期疗效。方法：选择我科2001-2011年收治的强直性脊柱炎髋关节受累的患者50例,在高频超声引导下于髋关节局部注射依那西普50mg,每周1次,连用4次。分别在注射前、注射后2、4、8周观察患者的BASDAI、BASFI、脊柱痛VAS、患者总体评价（PGA）VAS、夜间痛VAS、血沉、CRP和Harris功能评分,同时记录患者出现的不良反应。结果：依那西普治疗2周时,30例达ASAS20的缓解（60％）,13例（26％）达到ASAS50的缓解,8例（16％）达到ASAS70的缓解;治疗8周时,ASAS20／50／70的缓解率分别为38例（64％）、21例（42％）、15例（30％）,其中Harris评分达70以上者占总人数的90％,80分60％,90分30％,1例患者缓解不明显,4例患者处于70分以下,但疾病活动度情况改善。结论：依那西普可有效改善强直性脊柱炎髋关节受累患者的关节症状,降低疾病活动强度,且无明显药物不良反应。     

间歇性低压低氧预处理对大鼠放射性肝脏损伤的作用及肝脏组织TNF-α、HIF-1α表达的影响

目的:探讨间歇性低压低氧预处理对大鼠放射性肝脏损伤的保护作用及肝脏组织TNF-α、HIF-1α表达的影响。方法:将24只健康SPF级SD大鼠随机分为对照组(C)、照射组(R)、间歇性低压低氧预处理联合照射组(IHHP+R),于照射后6小时处死小鼠切取2块肝脏组织,采用HE染色观察肝脏的病理形态学变化,免疫组化检测肝脏TNF-α、HIF-1α的表达。结果:R组大鼠肝脏切片镜下可见中央静脉充血,肝窦淤血,肝细胞肿大,出现片状嗜酸样变性;IHHP+R组大鼠肝脏切片镜下可见中央静脉充血、肝窦淤血、肝细胞肿大程度均较R组减轻,未见嗜酸样变性。与C组相比,与C组相比,TNF-α在R组表达明显增高(P0.05),IHHP+R组TNF-α表达显著低于R组(P0.05)。C组和R组HIF-1α的表达比较差异无统计学意义(P0.05),但HIF-1α在IHHP+R组高表达,且显著高于R组(P0.05)。IHHP+R组TNF-α、HIF-1α表达呈负相关(r=-0.745,p=0.034)。结论:间歇性低压低氧处理可显著改善大鼠放射性肝脏损伤,可能与其提高HIF-1α的表达,进而抑制TNF-α的表达,减轻炎症反应有关。     

TNF-α在宫颈息肉组织中的表达及意义

目的:检测宫颈息肉组织中肿瘤坏死因子TNF-α的表达,并探讨其在宫颈息肉发病机制中的作用.方法:对150例患者宫颈息肉组织及137例宫颈管内膜组织分别进行TNF-α免疫组织化学染色和免疫印迹检测.结果:免疫组化检查发现TNF-α主要表达在宫颈息肉组织中的浆细胞胞质内,与对照组的表达比较差异有统计学意义(t值分别为2.258,P值均＜0.05).而且免疫印迹检查发现TNF-α蛋白在宫颈息肉组织中特异性表达强度高于对照组.结论:TNF-α在宫颈息肉组织中表达增高,对其发病起着一定的作用.     

软骨复合物对小鼠类风湿性关节炎的预防作用

目的观察口服软骨复合物对类风湿性关节炎（rheumatoid arthritis,RA）的预防作用。方法口服软骨复合物两周后,再注射弗氏完全佐剂（Freund’s complete adjuvant,FCA）诱发小鼠RA模型,通过观察小鼠关节炎分数的变化,测定小鼠各器官的指数,检测小鼠血清中一氧化氮（nitric oxide,NO）和肿瘤坏死因子-α（TNF-α）水平以及关节组织病理学的变化来评价口服软骨复合物对类风湿性关节炎的预防作用。结果软骨复合物能较有效的改善关节的肿胀度,并显著地提高小鼠的胸腺指数（P〈0．01）,显著地提高脾指数（P〈0．05）,明显降低NO和TNF-α水平;组织病理学显示给药组关节的变形破坏得到减轻。结论软骨复合物能有效地起到预防佐剂性关节炎的作用,然而其治疗作用还有待进一步研究。     

T7启动子作用下抗人TNF-α单链抗体的表达

基因工程技术构建的抗人TNF-α单链抗体克隆入表达载体pET15b-Etag中,在T7启动子的作用下,经0.1 mmol/L IPTG诱导,在大肠杆菌BL21(DE3)中获得高效表达,其表达量占菌体总蛋白的38%.表达产物大部分以包涵体形式存在,而一小部分以有活性的可溶性形式出现于细菌的外周质中.这部分可溶性的表达产物占菌体总蛋白的6%,经双抗体夹心法和斑点印迹分析表明它具有抗原结合活性.     

百令胶囊联合厄贝沙坦片对膜性肾病患者MMP-9, MMP-3和TIMP-1水平的影响

目的:探究百令胶囊联合厄贝沙坦片对膜性肾病患者基质金属蛋白酶-9、3和金属蛋白酶组织抑制物-1影响。方法:收集我院肾内科收治的膜性肾病患者98例,根据随机对照表分为对照组和试验组,每组49例。对照组给予厄贝沙坦片治疗,试验组联合百令胶囊治疗。对比分析两组患者的临床疗效、血清Scr、BUN、UA、Ccr、尿蛋白、MMP-9、MMP-3及TIMP-l水平以及不良反应的发生情况。结果:治疗后,对照组临床总有效率为81.63%,显著低于试验组的95.92%(P0.05)。两组治疗后血清Scr、BUN、UA、MMP-9、MMP-3、TIMP-l水平均显著降低,且试验组显著低于对照组(P0.05),Ccr水平升高,且试验组显著高于对照组(P0.05)。对照组不良反应发生率为10.20%,试验组为6.25%,差异无统计学意义(P0.05)。结论:百令胶囊联合厄贝沙坦片对膜性肾病患者的临床疗效显著,安全性较高,可能与其显著降低MMP-9、MMP-3和TIMP-1水平有关。     

Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3

Matrix metalloproteinases (MMPs), a group of more than 20 zinc-containing endopeptidases, are up-regulated in many diseases, but the use of MMP inhibitors for therapeutic purposes has often been disappointing, possibly for the limited specificity of the drugs used in clinical trials. In principle, individual MMPs could be specifically drugged by monoclonal antibodies, either by inhibition of their catalytic activity or by antibody-based pharmacodelivery strategies. In this article we describe the isolation and affinity maturation of recombinant antibodies (SP1, SP2, SP3) specific to the murine catalytic domains of MMP-1A, MMP-2 and MMP-3. These novel reagents allowed a systematic comparative immunofluorescence analysis of the expression patterns of their cognate antigens in a variety of healthy, cancerous and arthritic murine tissues. While all three MMPs were strongly expressed in tumor and arthritis specimens, MMP-1A was completely undetectable in the normal tissues tested, while MMP-2 and MMP-3 exhibited a weak expression in certain normal tissues (e.g., liver). The new antibodies may serve as building blocks for the development of antibody-based therapy strategies in mouse models of pathology.     

Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand

Soluble Fas ligand (sFasL) is released from the cell surface by matrix metalloproteinases (MMPs), one of which is MMP-7. We have reported that MMP-7-generated sFasL is pro-apoptotic in both in vitro and in vivo systems. However, there are contradictory reports that the soluble form of FasL is inactive or anti-apoptotic, resulting in significant controversy in the literature. One potential explanation for these discrepancies is that forms of sFasL with different amino-terminal sequences have been demonstrated to have varying activities. Here we report that MMP-7 cleaves murine and human FasL at sites that are distinct from previously reported cleavage sites resulting in production of novel forms of sFasL. Cleavage of FasL by MMP-7 occurs at the leucine residues in the sequence "ELAELR" within the region between the transmembrane and trimerization domains. When this site is unavailable, a more c-terminal site, "SL," is cleaved. MMP-7 differentially processes murine and human FasL since it cleaves human FasL not only at the "ELAELR" site but also at a previously identified site. Additionally, MMP-3, but not MMP-2, was found to have the same cleavage specificity for murine FasL as MMP-7. We conclude that the controversy regarding the biological activity of sFasL may be explained, in part, by the generation of distinct forms of sFasL as a result of cleavage at specific sequences.     

Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453

Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453 have been solved at 2.01 and 2.37A resolutions, respectively. The results revealed that the binding modes for this inhibitor to MMP-3 and -13 were quite similar. However, subtle comparative differences were observed at the bottom of S1' pockets, which were occupied with the guanidinomethyl moiety of the inhibitor. A remarkable feature of the inhibitor was the deep penetration of its long aliphatic chain into the S1' pocket and exposure of the guanidinomethyl moiety to the solvent.     

Functional analysis of aortic endothelial cells expressing mutant PDGF receptors with respect to expression of matrix metalloproteinase-3

Platelet-derived growth factor (PDGF) stimulates expression of matrix metalloproteinases (MMPs), including stromelysin-1 (MMP-3). Induction of these expressions is known to occur during the course of atherosclerosis, tumor invasion, and metastasis. We investigated PDGF-alpha receptor (alphaR)- and beta receptor (betaR)-mediated signaling pathways for the expression of MMP-3 and invasion activity using porcine aortic endothelial (PAE) cells with stable expression of normal or mutated PDGF receptors. RT-PCR and Western blot analyses revealed that PDGF-BB induces MMP-3 expression in PAE cells that exclusively express either the PDGF-alphaR or the -betaR, but not in non-transfected control cells. To identify the signals necessary for PDGF receptor-mediated induction of MMP-3 expression, several lines of PAE cells expressing mutant PDGF receptors were further analyzed. Cells expressing mutant PDGF receptors unable to associate with Src or PLCgamma, retained the ability to induce MMP-3 expression as a result of PDGF-BB stimulation. However, incubation with PDGF-BB did not induce MMP-3 expression in cells expressing a mutant PDGF-betaR unable to associate with phosphatidylinositol 3(')-kinase (PI3K). LY294002, a PI3K inhibitor, reduced PDGF-BB-stimulated MMP-3 expression in PAE cells expressing wild-type PDGF receptors. In contrast, PDGF-BB induced MMP-3 expression in the presence of U-73122, a PLCgamma inhibitor. Moreover, PDGF-BB enhanced the invasiveness of cells expressing wild type PDGF-beta receptors, but not of cells expressing mutant PDGF-betaRs impaired in their ability to associate with PI3K. In light of these results, it appears that PDGF-BB is capable of inducing MMP-3 expression through both the PDGF-alphaR and the -betaR, and the effects are contributed by the PI3K-mediated transduction pathways.     

Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy

MMP-2/MMP-8 is established as one of the most important metalloenzymes for targeting cancer. A series of dihydropyrazothiazole derivatives (E1–E18) bearing a salicylaldehyde group linked to Pyrazole ring were designed, synthesized, and evaluated for their pharmacological activity as MMP-2/MMP-8 inhibitors. Among them, compound E17 exhibited most potent inhibitory activity (IC₅₀?=?2.80?μM for MMP-2 and IC₅₀?=?5.6?μM for MMP-8), compared to the positive drug CMT-1 (IC₅₀?=?1.29?μM). Compounds (E1–E18) were scrutinized by CoMFA and CoMSIA techniques of Three-dimensional quant. structure-activity relationship (3D-QSAR), as well as a docking simulation. Moreover, treatment with compound E4 could induce MCF-7 cell apoptosis. Overall, the biological profile of E1–E18 may provide a research basis for the development of new agents against cancer.     

周期性静水压对人软骨细胞IL-1β和MMP-3代谢的影响

目的：以正常成人软骨细胞及OA软骨细胞为研究对象,探讨在静水压作用下正常软骨细胞IL-1B和MMP-3代谢的变化,以及与OA软骨细胞之间的差异。同时观察在力学信号刺激下软骨细胞的IL-1β和MMP-3代谢有无相关性。方法：将体外培养的正常成人膝关节软骨第3代软骨细胞随机分为加压组和对照组。甲苯胺蓝及Ⅱ型胶原免疫细胞化学染色进行细胞鉴定。将加压组细胞放入高压恒温静水压加压系统,冲入含有95％的空气和5％的CO2混合气体,以10MPa进行加压2h,共加压5d。分别于加压前、加压第3天、加压第5天后取加压组、对照组和OA组细胞培养液检测IL-1β、MMP-3含量。同时采用MTT法分析3组细胞的增殖情况。对三组细胞中IL-1β与MMP-3的水平做双变量相关分析,采用方差分析对三组标本间的IL-1β、MMP-3含量进行比较。结果：各组细胞IL-1β与MMP-3两者间存在正相关关系。OA组细胞中IL-1β与MMP-3含量高于加压组和对照组,加压组高于对照组。加压组、OA组软骨细胞的生长曲线与对照组相比增殖高峰降低,平台时间缩短。结论：10MPa间歇性静水压加压可抑制软骨细胞增殖,增加IL-1β与MMP-3分泌。     

周期性静水压对人软骨细胞IL-1beta和MMP-3 代谢的影响

目的：以正常成人软骨细胞及OA软骨细胞为研究对象,探讨在静水压作用下正常软骨细胞IL-1beta和MMP-3 代谢的变化,以及与OA软骨细胞之间的差异。同时观察在力学信号刺激下软骨细胞的IL-1beta和MMP-3 代谢有无相关性。方法：将体外培养的正常成人膝关节软骨第3 代软骨细胞随机分为加压组和对照组。甲苯胺蓝及Ⅱ型胶原免疫细胞化学染色进行细胞鉴定。将加压组细胞放入高压恒温静水压加压系统,冲入含有95％的空气和5％的CO2混合气体,以10MPa 进行加压2h,共加压5d。分别于加压前、加压第3 天、加压第5 天后取加压组、对照组和OA 组细胞培养液检测IL-1beta、MMP-3 含量。同时采用MTT 法分析3 组细胞的增殖情况。对三组细胞中IL-1beta与MMP-3 的水平做双变量相关分析,采用方差分析对三组标本间的IL-1beta、MMP-3 含量进行比较。结果：各组细胞IL-1beta与MMP-3 两者间存在正相关关系。OA组细胞中IL-1beta与MMP-3含量高于加压组和对照组,加压组高于对照组。加压组、OA组软骨细胞的生长曲线与对照组相比增殖高峰降低,平台时间缩短。结论：10MPa 间歇性静水压加压可抑制软骨细胞增殖,增加IL-1beta与MMP-3 分泌。     

明胶酶及肿瘤抑制基因pten在喉鳞状细胞癌中表达的研究

目的探讨喉鳞癌中明胶酶MMP-2、MMP-9及肿瘤抑制基因PTEN的表达及其相关性.方法应用S-P免疫组化法检测68例喉鳞癌、9例异型增生及15例正常喉粘膜的MMP-2、MMP-9及PTEN蛋白表达.结果(1)MMP-2、MMP-9阳性表达率:喉鳞癌中分别为73.53%、79.41%,均显著高于异型增生表达率(44.44%、22.22%)及正常喉粘膜表达率(13.33%、20.00%),P<0.05;伴淋巴结转移的喉鳞癌组分别为96.88%、100%,显著高于未转移组52.78%、61.11%,P<0.01.T3-T4期MMP-9的表达(100%)高于T1-T2期(53.33%),P<0.01.(2)PTEN在异型增生喉上皮中高表达率66.67%,显著高于正常喉上皮(13.33%)P<0.01,喉鳞癌中高表达率44.12%,阴性表达率为22.06%,总异常率(66.17%)与正常组(13.33%)间差异显著,P<0.05.PTEN高表达率在伴淋巴结转移组(25.00%)低于未转移组(61.11%),P<0.05;与组织学分级负相关(P<0.01).(4)喉鳞癌中MMP-2与MMP-9表达间呈正相关,二者分别与PTEN表达呈负相关.结论MMP-2、MMP-9表达增强及PTEN表达减弱对喉鳞癌的浸润转移起促进作用且相互协同,是喉鳞癌侵袭的重要标志物,其中PTEN异常是一早期事件.     

依达拉奉联合克林澳对急性脑梗死患者血清MMP-3、MMP-9、TIMP-1、EPCs的影响及疗效观察

目的:研究依达拉奉联合克林澳对急性脑梗死患者血清MMP-3(基质金属蛋白酶-3)、MMP-9(基质金属蛋白酶-9)、TIMP-1(组织基质金属蛋白酶抑制剂1)、EPCs(内皮祖细胞)的影响及疗效观察。方法:选取我院收治的114例急性脑梗死患者,按照随机数表法分为联合治疗组(n=57)和单独治疗组(n=57)。单独治疗组仅应用依达拉奉治疗,联合治疗组则联合克林澳治疗。观察并比较两组患者临床治疗效果、NIHSS(美国国立卫生研究院卒中量表)评分变化情况、实验室指标水平变化情况、血脂水平变化情况以及不良反应发生情况。结果:治疗后,联合治疗组基本痊愈和显著进步的患者达到49例,其总有效率为85.96%,而单独治疗组基本痊愈和显著进步的患者仅为39例,其总有效率为68.42%,两组比较差异显著(P0.05)。治疗14 d和28 d后,患者的评分均较治疗前有明显下降,同时,联合治疗组下降水平明显优于单独治疗组(P0.05)。两组患者MMP3和MMP9水平较治疗前显著下降,而TIMP-1和EPCs水平则明显上升,且联合治疗组MMP3和MMP9水平下降情况和TIMP-1和EPCs水平上升情况均明显优于单独治疗组(P0.05)。治疗14 d和28 d后,患者血脂各指标水平均较前一次测量有明显下降,且单独治疗组较联合治疗组下降更为明显(P0.05)。联合治疗组不良反应发生率为5.26%;单独治疗组不良反应发生率为10.53%,不良反应发生率比较无统计学意义(P0.05)。结论:依达拉奉联合克林澳应用于治疗急性脑梗死患者疗效确切,有效改善血清MMP-3、MMP-9、TIMP-1、EPCs以及患者血脂异常情况,促进血管新生,保护患者脑组织。